The goal of this clinical trial is to evaluate the feasibility, safety and effectiveness of radiotherapy with fewer days of treatment and a higher dose of radiation each day in patients under 70 years of age diagnosed with a brain tumor known as glioblastoma.
Initial histological diagnosis of glioblastoma
Age > 18 and < 70 years;
Karnofsky Performance Status > 70%;
Patient consent to participate in the study.
Patients submitted to any type of previous radiotherapy in the cranial region;
Multicentric tumors;
Contraindication to chemotherapy with temozolomide;
Contraindications for performing magnetic resonance imaging (MRI), such as the use of implants or metallic prostheses;
Single group
Hypofractionated Radiation Therapy
Radiation60 Gy in 20 fractions of 3 Gy
Feasibility of accrual and planning
Accrual of patients, timely and adequated planning of radiotherapy
Incidence of acute and late neurological toxicity
Incidence of headache, brain edema and brain radionecrosis will be classified according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Overall Survival and Progression Free Survival
Death from any cause and disease progression during treatment and follow-up time
Correlative science
Evaluation of circulating tumor cells in the blood
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
